Accelerating implementation of biomedical research advances: Critical elements of a successful 10 year Cystic Fibrosis Foundation healthcare delivery improvement initiative

BMJ Quality and Safety

Volumn 23, Issue SUPPL1, 2014, Pages

  Marshall, Bruce C ^a   Nelson, Eugene C ^b  

^a CYSTIC FIBROSIS FOUNDATION   (United States)

^b DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CYSTIC FIBROSIS; FOLLOW UP; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH CARE QUALITY; LUNG FIBROSIS; LUNG FUNCTION; MEDICAL RESEARCH; NUTRITIONAL STATUS; OUTPATIENT CARE; PATHOPHYSIOLOGY; SURVIVAL; TOTAL QUALITY MANAGEMENT; FEMALE; HUMAN; MALE; NON PROFIT ORGANIZATION; ORGANIZATION AND MANAGEMENT; TIME; UNITED STATES;

BIOMEDICAL RESEARCH; CYSTIC FIBROSIS; DELIVERY OF HEALTH CARE; FEMALE; FOUNDATIONS; HEALTH PLAN IMPLEMENTATION; HUMANS; MALE; QUALITY ASSURANCE, HEALTH CARE; QUALITY IMPROVEMENT; TIME FACTORS; UNITED STATES;

EID: 84896520923     PISSN: 20445415     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmjqs-2013-002790     Document Type: Article

References (41)

1. Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathologic study. Am J Dis Child 1938;56:344-99.
2. Kessler WR, Andersen DH. Heat prostration in fibrocystic disease of the pancreas and other conditions. Pediatrics 1951;8:648-56.
3. Di Sant'Agnese PA, Darling RC, Perera GA, et al. Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas; clinical significance and relationship to the disease. Pediatrics 1953;12:549-63.
4. Gibson LE, Cooke RE. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 1959;23:545-9.
5. Quinton PM. Chloride impermeability in cystic fibrosis. Nature 1983;301:421-2.
6. Knowles MR, Stutts MJ, Spock A, et al. Abnormal ion permeation through cystic fibrosis respiratory epithelium. Science 1983;221:1067-70.
7. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-73.
8. Anderson MP, Rich DP, Gregory RJ, et al. Generation of cAMP-activated chloride currents by expression of CFTR. Science 1991;251:679-82.
9. Griesenbach U, Alton EW. Moving forward: cystic fibrosis gene therapy. Hum Mol Genet 2013;22(R1):R52-8.
10. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637-42.
11. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23-30.
12. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. JAMA 2003;290:1749-56.
13. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-40.
14. Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009;135:1223-32.
15. McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008;178:921-8.
16. Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013;187:680-9.
17. Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007;176:957-69.
18. Trivedi BP. Doorway to a cure. Discover, 2013.
19. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663-72.
20. Rowe S, Heltshe SL, Gonska T, et al. Results of the G551D observational study: the effect of ivacaftor in G551D patients following FDA approval. Pediatr Pulmonol 2013;278 (Suppl 36).
21. Mogayzel PJ, Dunitz J, Marrow LC, et al. Improving chronic care delivery and outcomes: The impact of the Cystic Fibrosis Care Center Network. BMJ Qual Saf 2014;23:i3-8.
22. Cystic Fibrosis Foundation Patient Registry: 2012 Annual Data Report to the Center Directors. Bethesda, Maryland, 2013.
23. Doershuk CF, Matthews LW, Tucker AS, et al. Evaluation of a prophylactic and therapeutic program for patients with cystic fibrosis. Pediatrics 1965;36:675-88.
24. Mantle DJ, Norman AP. Life-table for cystic fibrosis. BMJ 1966;2:1238-41.
25. Moore BM, Laguna TA, Liu M, et al. Increased adherence to CFF practice guidelines for pulmonary medications correlates with improved FEV1. Pediatr Pulmonol 2013;48:747-53.
26. http://www.cdc.gov/nccdphp/dnpao/growthcharts/resources/sas.htm.
27. Schechter MS, Fink AK, Homa K, et al. The Cystic Fibrosis Foundation Registry as a tool for use in quality improvement. BMJ Qual Saf 2014;2014;23:i9-14.
28. Godfrey MM, Oliver BJ. Accelerating the rate of improvement in cystic fibrosis care: the learning and leadership collaborative. BMJ Qual Saf 2014;23:i23-32.
29. Boyle MP, Sabadosa KA, Quinton HB, et al. Key findings of the Cystic Fibrosis Foundation's US clinical practice benchmarking project. BMJ Qual Saf 2014;23:i15-22.
30. Richards KM, Lester MK, Chin MJ, et al. A preliminary evaluation of the effectiveness of the Cystic Fibrosis Foundation mentoring program for respiratory care. Respir Care 2013;58:764-9.
31. Wenger E. Communities of practice: learning, meaning, and identity. New York: Cambridge University Presss, 1998.
32. Sabadosa KA, Batalden P. The interdependent roles of patients, families and professionals in cystic fibrosis: a system for the co-production of health care and its improvement. BMJ Qual Saf 2014;23:i90-94.
33. Nelson EC, Godfrey MM, Batalden PB, et al. Clinical microsystems, part 1. The building blocks of health systems. Jt Comm J Qual Patient Saf 2008;34:367-78.
34. Moran A, Becker D, Casella SJ, et al. Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review. Diabetes Care 2010;33:2677-83.
35. Casalino LP, Rittenhouse DR, Gillies RR, et al. Specialist physician practices as patient-centered medical homes. N Engl J Med 2010;362:1555-8.
36. Dentzer S. Rx for the 'blockbuster drug' of patient engagement. Health Aff (Millwood) 2013;32:202.
37. Homa K, Sabadosa KA, Nelson EC, et al. Development and validation of a cystic fibrosis patient and family member experience of care survey. Qual Manag Health Care 2013;22:100-16.
38. Daniels T, Goodacre L, Sutton C, et al. Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers. Chest 2011;140:425-32.
39. Lauer MS, D'Agostino RB Sr. The randomized registry trial - the next disruptive technology in clinical research? N Engl J Med 2013;369:1579-81.
40. Nelson EC, Batalden PB, Godfrey MM, et al. Value by design: developing clinical microsystems to achieve organizational excellence. San Francisco, CA: Jossey-Bass, 2011.
41. Institute of Medicine (IOM). The learning healthcare system: workshop summary. Washington, DC: National Academies Press, 2007.